Identification of the Human UDP-Glucuronosyltransferases Involved in the Glucuronidation of Combretastatin A-4
- 7 April 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 38 (7), 1141-1146
- https://doi.org/10.1124/dmd.109.031435
Abstract
The stilbenic compound (Z)-combretastatin A-4 (CA-4) has been described as a potent tubulin polymerization inhibitor. In vivo, CA-4 binds to tubulin and inhibits microtubule depolymerization, which results in morphological changes in proliferating endothelial cells. Combretastatin A-4 prodrug phosphate is a leading vascular disrupting agent and is currently being evaluated in multiple clinical trials as a treatment for solid tumors. The aim of this study was to identify and characterize the UDP-glucuronosyltransferase (UGT) isoforms involved in CA-4 glucuronidation by incubation with human liver microsomes and a panel of nine liver-expressed recombinant UGT Supersomes (1A1, 1A3, 1A4, 1A6, 1A9, 2B4, 2B7, 2B15, and 2B17). As we observed, the high rate of formation of CA-4 glucuronide (Vmax = 12.78 ± 0.29 nmol/min/mg protein) and the low Km (6.98 ± 0.65 μM) denoted that UGT1A9 was primarily responsible for the in vitro glucuronidation of CA-4. UGT1A6 was also a significant contributor to CA-4 glucuronidation (Vmax = 3.95 ± 0.13 nmol/min/mg protein and S50 = 44.80 ± 3.54 μM). Furthermore, we demonstrated that the kinetics of CA-4 glucuronidation with liver microsomes but also with a panel of recombinant UGTs is atypical as it fits two different models: the substrate inhibition and also the sigmoidal kinetic model. Finally, experiments conducted to inhibit the glucuronosyltransferase activity in the human liver microsomes assay showed that phenylbutazone, trifluoperazine, propofol, and 1-naphthol effectively inhibited CA-4 glucuronidation.Keywords
This publication has 17 references indexed in Scilit:
- Quantitative Analysis of UDP-Glucuronosyltransferase (UGT) 1A and UGT2B Expression Levels in Human LiversDrug Metabolism and Disposition, 2009
- In vitroandin vivophase II metabolism of combretastatin A-4: Evidence for the formation of a sulphate conjugate metaboliteXenobiotica, 2009
- Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain ReactionPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2008
- In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathwayBiochemical Pharmacology, 2008
- Efficacy of Selected Natural Products as Therapeutic Agents against CancerJournal of Natural Products, 2008
- Product Inhibition of UDP-Glucuronosyltransferase (UGT) Enzymes by UDP Obfuscates the Inhibitory Effects of UGT SubstratesDrug Metabolism and Disposition, 2007
- In Vitro Metabolism Study of Combretastatin A-4 in Rat and Human Liver MicrosomesDrug Metabolism and Disposition, 2007
- KINETIC CHARACTERIZATION OF THE 1A SUBFAMILY OF RECOMBINANT HUMAN UDP-GLUCURONOSYLTRANSFERASESDrug Metabolism and Disposition, 2005
- Atypical kinetic profiles in drug metabolism reactions.Drug Metabolism and Disposition, 2002
- Synthesis of water-soluble sugar derivatives of combretastatin A-4Journal of the Chemical Society, Perkin Transactions 1, 1995